A synthetic BLT2 agonist accelerates wound healing and enhances re-epithelialization in C57BL/6J and db/db mice. DMSO vehicle or a synthetic BLT2 agonist (10 µM in Vaseline) was applied daily to the skin wounds of C57BL/6J (B6) mice (A–E) and db/db mice (F–J). (A and F) Wound closure rate in C57BL/6J (A, n = 3 mice per group) and db/db (F, n = 8–10 mice per group) mice. (B and G) Gross appearance of the wounds in C57BL/6J mice on day 6 (B, n = 3 mice per group) and db/db mice at the indicated days (G, n = 8–10 mice per group). Bar, 1 mm. (C and H) Morphometric analysis of wounded skin. Re-epithelialization (top), wound length (middle), and Ki67-positive keratinocyte proliferation (bottom; n = 5 mice per group, two sites per mouse) were evaluated in HE-stained tissue sections. (D and I) Representative HE-stained sections of the wounds at 3 d after skin punching. Arrows, wound margin; arrowheads, epithelial leading edge. Bars, 100 µm. (E and J) Representative Masson’s trichrome–stained sections of the wounds (E, day 6; J, day 7; n = 5 mice per group). Bars, 100 µm. Data represent the mean ± SEM. **, P < 0.01; *, P < 0.05; N.S., not significant (A and F, two-way ANOVA; C and H, unpaired Student’s t test). All the results are representative of at least two independent experiments.